Clinical trial · Observational
Corellation of Mutations, TILs and Age in Breast Cancer
Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Old Patients With Breast Cancer
NCT04033965CI-TRIAL-00039752completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Age may pertain to different tumor genotype characteristics which may interfere with treatment efficacy and prognosis. The investigators investigated the distribution and prognostic effect of mutations (mut) and tumor infiltrating lymphocyte (TILs) in young and elderly early breast cancer patients (pts).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Corellation of Mutations, TILs and Age in Breast Cancer | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- women <35 with early breast cancer
- interventionNames
- Genetic: Corellation of Mutations, TILs and Age in Breast Cancer
- label
- women>65 years old with early breast cancer
- interventionNames
- Genetic: Corellation of Mutations, TILs and Age in Breast Cancer
Primary outcomes (6)
- measure
- Assessment of the prevalence of gene mutations in women <=35 years old with early breast cancer.
- timeFrame
- Up to 13 years
- measure
- Assessment of the prevalence of gene mutations in women >65years old with early breast cancer.
- timeFrame
- Up to 13 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * women with early breast cancer \<35 years old or \>65 years old Exclusion Criteria: * NA
References
Publications (32)
- BACKGROUNDGnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009 Mar;208(3):341-7. doi: 10.1016/j.jamcollsurg.2008.12.001. Epub 2009 Jan 21. PMID 19317994
- BACKGROUNDStickeler E. Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer. Breast Care (Basel). 2011;6(3):193-198. doi: 10.1159/000329471. Epub 2011 Jun 14. PMID 21779224
- BACKGROUNDBonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer. 1995 Jul 17;62(2):138-44. doi: 10.1002/ijc.2910620205. PMID 7622286
- BACKGROUNDSweeney C, Blair CK, Anderson KE, Lazovich D, Folsom AR. Risk factors for breast cancer in elderly women. Am J Epidemiol. 2004 Nov 1;160(9):868-75. doi: 10.1093/aje/kwh276. PMID 15496539
- BACKGROUNDGomez-Flores-Ramos L, Castro-Sanchez A, Pena-Curiel O, Mohar-Betancourt A. Molecular Biology In Young Women With Breast Cancer: From Tumor Gene Expression To DNA Mutations. Rev Invest Clin. 2017 Jul-Aug;69(4):181-192. doi: 10.24875/ric.17002225. PMID 28776603
- BACKGROUNDAzim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014 Aug 27;16(4):427. doi: 10.1186/s13058-014-0427-5. PMID 25436920
- BACKGROUNDAebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000 May 27;355(9218):1869-74. doi: 10.1016/s0140-6736(00)02292-3.